SWK (NASDAQ:SWKH) Trading Down 4.1% – Should You Sell?

SWK Holdings Co. (NASDAQ:SWKH) shares traded down 4.1% on Friday . The company traded as low as $15.63 and last traded at $15.80. 67,931 shares traded hands during trading, an increase of 530% from the average session volume of 10,786 shares. The stock had previously closed at $16.47.

SWK Stock Performance

The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $193.28 million, a PE ratio of 16.99 and a beta of 0.35. The firm’s 50-day simple moving average is $16.36 and its 200-day simple moving average is $16.80.

Institutional Investors Weigh In On SWK

Several hedge funds have recently made changes to their positions in the company. Barclays PLC increased its holdings in SWK by 185.0% during the third quarter. Barclays PLC now owns 4,461 shares of the company’s stock valued at $77,000 after buying an additional 2,896 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of SWK in the 2nd quarter valued at $172,000. Dimensional Fund Advisors LP increased its holdings in shares of SWK by 85.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 30,109 shares of the company’s stock valued at $511,000 after acquiring an additional 13,892 shares during the period. SkyView Investment Advisors LLC raised its position in shares of SWK by 7.7% in the 2nd quarter. SkyView Investment Advisors LLC now owns 31,165 shares of the company’s stock worth $529,000 after acquiring an additional 2,234 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in shares of SWK during the 3rd quarter worth $589,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

SWK Company Profile

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.